| Code | CSB-RA015007MB21HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar of ublituximab, targeting MS4A1 (CD20)—a B-cell surface marker expressed from late pre-B cells through mature/memory B cells, with expression typically lost upon terminal differentiation into plasmablasts/plasma cells. As a lineage-restricted antigen, CD20-targeting tools are widely used to interrogate B-cell–driven immunobiology, including B-cell depletion kinetics and downstream effects on immune signaling networks.
Ublituximab (marketed as BRIUMVI®; ublituximab-xiiy) is a glycoengineered anti-CD20 IgG1 monoclonal antibody with reduced Fc fucosylation to increase FcγR engagement and support enhanced ADCC-type effector activity compared with non-glycoengineered anti-CD20 formats. It is FDA-approved for relapsing forms of multiple sclerosis. This biosimilar provides the antibody component alone, enabling researchers to study CD20 target engagement, Fc-effector–dependent B-cell depletion mechanisms (ADCC/ADCP vs CDC), and related assay readouts (e.g., FcγRIIIa-variant sensitivity) in controlled experimental systems—without confounding payloads or delivery modalities.
There are currently no reviews for this product.